Salzburg

• ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I … Recruiting
  2023-505758-17-00 4 2025-08-21 endocrine-responsive HER2-negative early breast cancer
• Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D … Recruiting
  2024-515561-34-01 6 2025-08-04 Acute ischemic stroke with recent ingestion of direct oral anticoagula
• Impact of beta blocker administration on aortic valve replacement Recruiting
  2024-518731-11-00 6 2025-08-04 Aortic stenosis
• A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with … Recruiting
  2024-512583-57-00 5 2025-07-30 HER2-positive locally advanced or metastatic gastric or gastroesophage
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting
  2024-520154-38-00 5 2025-07-29 Acute Myeloid Luekemia
• A Study to Assess the Adverse Events and Change in Disease Activity of Multiple Treatment Combinations with Telisotuzumab Adizutecan in Part … Recruiting
  2024-512981-33-00 4 2025-07-09 Metastatic Colorectal Cancer
• A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis Recruiting
  2025-520705-12-00 4 2025-06-24 Colitis Ulcerative
• Phase 3 Study of I-DXd Versus Docetaxel in mCRPC Recruiting
  2024-517423-40-00 5 2025-06-23 Metastatic Castration-Resistant Prostate Cancer
• A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's … Recruiting
  2023-509391-42-00 11 2025-06-02 Chron's Disease
• A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 o … Recruiting
  2024-517101-87-00 5 2025-05-26 Intestinal Malabsorption
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C … Recruiting
  2024-517422-25-00 5 2025-05-22 Metastatic Castration-resistant Prostate Cancer (mCRPC)
• A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adult Patients Wi … Recruiting
  2024-515593-27-00 5 2025-05-08 relapsed or refractory mantle cell lymphoma (R/R MCL)
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa … Recruiting
  2024-516030-35-00 5 2025-04-30 Multiple myeloma
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell L … Recruiting
  2022-501489-24-00 5 2025-03-28 First-line treatment of adult subjects with high-risk large B-cell lym
• Study to evaluate efficacy and safety of inclisiran in children aged 6 to under 12 years of age with heterozygous familial hypercholesterole … Recruiting
  2024-514594-21-00 5 2025-03-13 Heterozygous Familial Hypercholesterolemia
• A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum Recruiting
  2024-514306-31-00 5 2025-02-13 Pyoderma gangrenosum
• A phase 3 study to evaluate petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of head and neck cancer Recruiting
  2023-510323-30-00 5 2025-01-24 First-line treatment of recurrent or metastatic PD-L1+ head and neck s
• Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma Recruiting
  2024-511188-26-00 5 2024-12-20 Relapsed/refractory multiple myeloma in patients who have received 1 t
• A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting
  2023-508813-18-00 4 2024-12-18 Refractory Focal Onset Epilepsy
• This is a study to evaluate safety and efficacy of Upadacitinib comparing to Dupilumab in children from 2 to less than 12 years of age with … Recruiting
  2023-504713-76-00 5 2024-12-03 Dermatitis atopic
• Study of Targeted Therapies for the Treatment of Adult Participants with Moderate to Severe Crohn’s Disease Recruiting
  2024-513009-30-00 4 2024-11-21 Moderate to Severe Crohn’s Disease
• HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t … Recruiting
  2024-514917-36-00 5 2024-11-21 Patients with High Risk Neuroblastoma
• A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment, in participants who have advanc … Recruiting
  2024-511319-91-00 5 2024-10-23 Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
• A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting
  2023-508539-30-00 4 2024-10-10 Refractory Focal Onset Epilepsy

Showing 73–96 of 282 trials